Shares of Dow component Merck (NYSE:MRK) are up more than 15% since the start of the year, and the company has reported mixed results lately; the sting of the FDA's rejection of its experimental insomnia drug was partially offset by investor excitement around data from a new cancer-fighting PD-1 drug, but the company has many more therapeutics in clinical development. As investors continue to watch Merck's drug development efforts, which therapeutics and events should they be focusing on? In the following video from The Motley Fool's health-care show Market Checkup, health-care analysts David Williamson and Max Macaluso discuss the upcoming catalysts that Merck investors can't ignore.
David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.